Drug intelligence / Profile preview

Abwiz Bio food allergy monoclonal antibody

Development stage: Preclinical
Lead developer: Abwiz Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Abwiz Bio food allergy monoclonal antibody is a preclinical-stage therapeutic candidate being developed by Abwiz Bio for the treatment of allergic diseases, specifically food allergy. Discovered using Abwiz Bio's proprietary phage display and WizAmp technology, the antibody's specific biological target has not been publicly disclosed. The program has received funding from the National Institutes of Health (NIH) to support the development of therapeutic antibodies for food allergies. As of early 2024, the candidate remains in the early discovery and preclinical phase of development.

Beyond the preview

Go deeper on Abwiz Bio food allergy monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abwiz Bio food allergy monoclonal antibody.

Explore the full profile